Recombinant Human Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17)

What is the role of ADAM17 in cerebrovascular function?

ADAM17 has emerged as a crucial regulator of cerebrovascular function, particularly in the context of neurodegenerative diseases. Research demonstrates that ADAM17 expression in cerebral microvessels is significantly reduced in Alzheimer's disease models compared to wild-type controls, while expression in whole brain lysates remains unchanged . This selective reduction in vascular ADAM17 appears to be associated with impaired endothelium-dependent vasodilation in cerebral arteries, which may contribute to cognitive dysfunction.

Methodologically, researchers can assess ADAM17's role in cerebrovascular function by:

• Isolating and purifying cerebral microvessels for protein expression analysis

• Measuring vasodilator responses in isolated cerebral arteries

• Assessing circumferential wall stress and elastic properties of cerebral vessels

• Correlating vascular function measures with cognitive performance

A key experimental approach is to manipulate ADAM17 expression specifically in cerebral vessels and measure subsequent changes in vascular reactivity and cognitive function. This can be achieved through targeted gene delivery systems such as AAV9-mediated approaches .

How does ADAM17 expression differ across brain regions and cell types?

ADAM17 expression varies significantly across different brain cell types and may be differentially regulated in disease states. While total brain ADAM17 expression may appear unchanged in Alzheimer's disease models, cell-specific analyses reveal important differences. For instance, cerebral microvessels from APP/PS1 mice show remarkably reduced ADAM17 expression compared to wild-type counterparts, highlighting the importance of cell-specific analyses .

Methodological considerations for studying cell-specific ADAM17 expression include:

• Centrifugation-based purification of cell populations (e.g., microvessels)

• Western immunoblotting with cell-specific markers

• Immunofluorescence co-labeling with cell-type specific antibodies

• Single-cell or single-nucleus RNA sequencing approaches

When examining ADAM17 expression, researchers should consider both protein and mRNA levels, as post-transcriptional regulation may play a significant role in determining functional ADAM17 activity.

What are the most effective methods for modulating ADAM17 expression in animal models?

Several approaches exist for modulating ADAM17 expression in animal models, with viral vector-mediated gene delivery being particularly effective. Based on current research, adeno-associated virus serotype 9 (AAV9) has proven successful for ADAM17 gene delivery in mouse models of Alzheimer's disease .

When designing gene delivery experiments:

• Compare targeted constructs (ADAM17-AAV9) with control vectors (e.g., eGFP-AAV9)

• Validate expression changes in target tissues (e.g., cerebral microvessels)

• Allow sufficient time (e.g., 3 months) for gene expression and physiological integration

• Confirm functional changes through appropriate assays (vascular reactivity, behavioral tests)

In the referenced study, ADAM17-AAV9 delivery successfully restored ADAM17 expression in cerebral microvessels of APP/PS1 mice to levels comparable to wild-type controls within 3 months of administration . Importantly, researchers should verify the specificity of expression and potential off-target effects in multiple tissues.

What cognitive assessment techniques best evaluate ADAM17's impact on brain function?

Multiple behavioral tests can assess cognitive function in relation to ADAM17 expression, with different tests capturing distinct aspects of memory and cognition. Based on experimental evidence, a comprehensive cognitive assessment battery should include:

Morris Water Maze (MWM)

• Assesses spatial learning and memory

• Key parameters: latency to reach target, time spent in platform area, platform line crossings

• Sensitive to ADAM17-related improvements in APP/PS1 mice

Novel Object Recognition (NOR)

• Evaluates recognition memory

• Key parameters: discrimination index (d2 ratio), recognition index (novel/familiar ratio)

• Shows significant improvements after ADAM17 re-expression

Spontaneous Y-Maze

• Measures working memory and exploratory behavior

• Key parameters: spontaneous alternations, number of arm entries

• Differentially affected by ADAM17 manipulation

Data from these tests can be represented as follows:

When designing cognitive assessment studies, control for confounding factors such as motor function, which can be evaluated through measures like swimming velocity in the MWM .

How does ADAM17 influence amyloid pathology in Alzheimer's disease models?

The relationship between ADAM17 and amyloid pathology appears complex. Research indicates that while ADAM17 re-expression in APP/PS1 mice significantly improves cognitive function and cerebrovascular responses, it does not significantly reduce amyloid-β plaque density in the cortex . This suggests that ADAM17's beneficial effects on cognition may operate through mechanisms largely independent of direct amyloid clearance.

Key methodological approaches to investigate this relationship include:

• Immunofluorescent staining for amyloid-β plaques

• Quantitative analysis of plaque density and size

• Correlation analyses between plaque metrics and ADAM17 expression

• Examination of soluble versus insoluble amyloid-β fractions

The data indicates that APP/PS1 mice exhibit significantly increased amyloid-β plaque numbers compared to wild-type controls, and this increase remains largely unchanged even after ADAM17 re-expression via AAV9 delivery . This finding suggests that ADAM17's cognitive benefits may be achieved through alternative pathways, potentially related to vascular function improvement rather than direct effects on amyloid pathology.

What molecular pathways are altered by ADAM17 modulation in neurodegeneration?

Proteomic analysis reveals that ADAM17 re-expression in APP/PS1 mice alters multiple molecular pathways relevant to Alzheimer's pathogenesis. Pathway analysis of differentially expressed proteins shows enrichment in several key biological processes and molecular functions .

Key altered pathways include:

• Regulation of APP and β-amyloid formation

• Biological and morphological quality regulatory processes

• Neuronal morphogenesis and development

• Cytoskeletal organization

Specific proteins identified as differentially regulated include:

• Septin

• Ankyrin-2

• Moesin

These proteins have been previously implicated in neurodegenerative diseases, including AD . Methodologically, mass spectrometry-based proteomic analysis provides a powerful approach for identifying molecular changes associated with ADAM17 modulation. Researchers should consider both direct ADAM17 substrates and downstream effectors when interpreting such data.

How does cerebrovascular ADAM17 affect vascular reactivity and mechanics?

ADAM17 plays a significant role in regulating cerebrovascular reactivity, with implications for neurovascular coupling and cerebral blood flow. Experimental evidence demonstrates that ADAM17 re-expression in APP/PS1 mice improves endothelium-dependent vasodilation in response to acetylcholine in isolated basilar arteries, restoring function to levels comparable to wild-type controls .

Advanced methodological approaches for assessing vascular reactivity include:

• Pressure myography of isolated cerebral vessels

• Measurement of responses to endothelium-dependent (acetylcholine) and -independent (sodium nitroprusside) vasodilators

• Assessment of passive mechanical properties in calcium-free conditions

• Calculation of biomechanical parameters including:

  • Circumferential wall stress

  • Incremental elastic modulus

  • Elastic modulus-wall stress relationships

These measurements can reveal both functional and structural vascular changes associated with ADAM17 expression. Importantly, while ADAM17 modulation affects endothelium-dependent vasodilation, research suggests it does not significantly alter responses to the endothelium-independent vasodilator sodium nitroprusside or passive mechanical properties of the vessels .

What are the limitations and considerations in translating ADAM17 research to clinical applications?

Several important limitations must be considered when interpreting ADAM17 research and its potential clinical applications:

Researchers should incorporate experimental designs that address these limitations, such as cell-specific ADAM17 manipulation, direct cerebral blood flow measurements, and comprehensive assessment of multiple cell types and pathways.

What research gaps remain in understanding ADAM17's role in neurovascular dysfunction?

Despite significant progress, several critical knowledge gaps remain in understanding ADAM17's role in neurovascular dysfunction:

• Substrate specificity in cerebral vessels: While ADAM17 cleaves numerous substrates, the specific targets relevant to cerebrovascular function in neurodegeneration remain incompletely characterized.

• Mechanistic pathways: The downstream signaling mechanisms linking reduced vascular ADAM17 to impaired vasodilation and cognitive dysfunction require further investigation .

• Cell-type specific effects: The relative contributions of ADAM17 in endothelial cells, smooth muscle cells, pericytes, and other neurovascular unit components need clarification.

• Temporal dynamics: The progression of ADAM17 expression changes throughout disease development and their relationship to cognitive decline warrant longitudinal studies.

• Interaction with comorbidities: How vascular risk factors like hypertension and diabetes interact with ADAM17 dysregulation remains poorly understood, despite their known relevance to dementia risk .

Future research should employ cell-specific manipulation approaches, temporal profiling, and models incorporating relevant comorbidities to address these gaps. Integration of human biomarker studies with preclinical models would strengthen translational potential.

What methodological advances would enhance ADAM17 research in neurodegeneration?

Several methodological advances could significantly enhance ADAM17 research in the context of neurodegeneration:

• Cell-specific expression systems: Development of tools for cell-type specific ADAM17 manipulation (endothelial, neuronal, glial) would help delineate cell-autonomous effects.

• In vivo activity measurements: Technologies for real-time monitoring of ADAM17 enzymatic activity in living brain tissue would improve understanding of dynamic regulation.

• Cerebral blood flow assessment: Integration of techniques like arterial spin labeling MRI or two-photon microscopy to directly assess microvascular blood flow in ADAM17-manipulated models .

• Human relevant models: Development of human iPSC-derived cerebral organoids or chimeric models incorporating human cells would enhance translational relevance.

• Multiplexed spatial proteomics: Advanced spatial proteomics approaches would help identify ADAM17 substrates and downstream effectors with cellular and anatomical precision.

• Systems biology approaches: Integration of proteomic, transcriptomic, and metabolomic data through computational modeling would help identify key regulatory networks affected by ADAM17 modulation. Recent proteomic analysis in APP/PS1 mice revealed numerous proteins and pathways altered by ADAM17 re-expression , providing a foundation for such approaches.

Implementing these methodological advances would address current limitations and accelerate progress in understanding ADAM17's role in neurodegeneration and its therapeutic potential.